Occam Recruits Michael Miller to the Board of BioXcel
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, has appointed Michael Miller to its Board of Directors. Michael brings multiple decades of strategic leadership and commercial growth experience in the pharmaceutical industry, having most recently served as Executive Vice President, U.S. Commercial at Jazz Pharmaceuticals. Michael led a 450+ person commercial team that generated $2.3 billion in revenues in 2020.
Prior to Jazz, he served in senior executive management positions with commercial, marketing, market access, and sales responsibilities at VIVUS, Genentech (until acquisition by Roche), Connetics Corporation, and ALZA Corporation.
Michael holds a B.S. in Finance from the University of San Francisco and an M.B.A. from San Francisco State University.
Recent Placements
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.